Knowledge and attitudes of Australian general practitioners towards medicinal cannabis: a cross-sectional survey

Author:

Karanges Emily A,Suraev Anastasia,Elias Natalie,Manocha Ramesh,McGregor Iain S

Abstract

ObjectivesTo examine the knowledge and attitudes of Australian general practitioners (GP) towards medicinal cannabis, including patient demand, GP perceptions of therapeutic effects and potential harms, perceived knowledge and willingness to prescribe.Design, setting and participantsA cross-sectional survey completed by 640 GPs (response rate=37%) attending multiple-topic educational seminars in five major Australian cities between August and November 2017.Main outcome measuresNumber of patients enquiring about medicinal cannabis, perceived knowledge of GPs, conditions where GPs perceived it to be beneficial, willingness to prescribe, preferred models of access, perceived adverse effects and safety relative to other prescription drugs.ResultsThe majority of GPs (61.5%) reported one or more patient enquiries about medicinal cannabis in the last three months. Most felt that their own knowledge was inadequate and only 28.8% felt comfortable discussing medicinal cannabis with patients. Over half (56.5%) supported availability on prescription, with the preferred access model involving trained GPs prescribing independently of specialists. Support for use of medicinal cannabis was condition-specific, with strong support for use in cancer pain, palliative care and epilepsy, and much lower support for use in depression and anxiety.ConclusionsThe majority of GPs are supportive or neutral with regards to medicinal cannabis use. Our results highlight the need for improved training of GPs around medicinal cannabis, and the discrepancy between GP-preferred models of access and the current specialist-led models.

Funder

The Lambert Initiative for Cannabinoid Therapeutics

Australian National Health and Medical Research Council

Publisher

BMJ

Subject

General Medicine

Reference31 articles.

1. Australian Institute of Health and Welfare (AIHW). National Drug Strategy Household Survey 2016: Detailed findings. Drug Statistics Series No. 31. 2017; https://www.aihw.gov.au/getmedia/15db8c15-7062-4cde-bfa4-3c2079f30af3/21028.pdf.aspx?inline=true (accessed Nov 2017).

2. Department of Health. Medicinal cannabis products: overview of regulation. Canberra: Therapeutic Goods Administration, 2017; https://www.tga.gov.au/medicinal-cannabis-products-overview-regulation. (accessed Nov 2017).

3. Department of Health. Access to medicinal cannabis products: steps to using access schemes. Canberra: Therapeutic Goods Administration, 2017; https://www.tga.gov.au/access-medicinal-cannabis-products-steps-using-access-schemes. (accessed Dec 2017).

4. Health Canada. Cannabis for Medical Purposes (FY 2017-18) - Licensed Producers: Monthly Data Ontario: Health Canada. Market Data. 2017; https://www.canada.ca/en/health-canada/services/drugs-health-products/medical-use-marijuana/licensed-producers/market-data.html (accessed Nov 2017).

5. The Royal Australian College of General Practitioners (RACGP). RACGP Position statement: Medicinal use of cannabis products. Melbourne: RACGP, 2016; https://www.racgp.org.au/support/policies/clinical-and-practice-management/racgp-position-statement-medicinal-use-of-cannabis-products/ (accessed Oct 2017).

Cited by 96 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3